| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.36B | 41.98B | 38.92B | 34.85B | 35.85B | 32.81B |
| Gross Profit | 9.80B | 10.24B | 9.01B | 6.93B | 8.81B | 8.56B |
| EBITDA | 4.81B | 5.76B | 4.52B | 3.12B | 4.33B | 3.88B |
| Net Income | 2.68B | 3.28B | 2.30B | 1.36B | 2.06B | 1.92B |
Balance Sheet | ||||||
| Total Assets | 60.66B | 65.65B | 58.40B | 51.30B | 50.32B | 46.04B |
| Cash, Cash Equivalents and Short-Term Investments | 5.72B | 7.37B | 7.46B | 5.08B | 6.26B | 6.53B |
| Total Debt | 1.35B | 1.26B | 1.22B | 1.15B | 1.24B | 1.34B |
| Total Liabilities | 21.18B | 22.32B | 20.44B | 17.40B | 18.27B | 16.66B |
| Stockholders Equity | 39.05B | 42.89B | 37.88B | 33.82B | 31.95B | 29.23B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 748.00M | 2.53B | -529.00M | -34.00M | 218.00M |
| Operating Cash Flow | 0.00 | 2.31B | 4.34B | 1.62B | 1.44B | 2.82B |
| Investing Cash Flow | 0.00 | -1.06B | -1.61B | -1.64B | -1.08B | -2.32B |
| Financing Cash Flow | 0.00 | -1.46B | -352.00M | -1.17B | -543.00M | -498.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥44.91B | 8.53 | ― | 3.53% | -3.45% | 30.52% | |
73 Outperform | ¥33.19B | 10.03 | ― | 0.13% | 9.78% | 40.00% | |
71 Outperform | ¥36.03B | 18.64 | ― | 3.45% | 4.17% | 23.25% | |
71 Outperform | ¥14.51B | 17.60 | ― | 1.81% | 9.07% | ― | |
66 Neutral | ¥28.12B | 11.91 | ― | 3.53% | 6.99% | -0.30% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ¥11.54B | 93.74 | ― | 1.06% | -9.63% | -1.71% |
Taki Chemical has revised the final-year targets of its Medium-Term Management Plan 2028, lifting net sales guidance from ¥42 billion to ¥44 billion and operating profit from ¥3 billion to ¥3.5 billion, while raising its return on equity goal from at least 6% to at least 7%. The upgrade follows stronger-than-expected results in the first two years, supported by higher fertilizer and water treatment chemical volumes, successful price hikes reflecting raw material cost increases, and broad-based segment growth, and the company aims to balance aggressive growth investments with disciplined capital efficiency and agile shareholder returns to enhance long-term corporate value.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen4266.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.
Taki Chemical Co. has updated its capital- and stock-price-conscious management policies after achieving record-high profits in fiscal 2025, driven by higher sales volumes in fertilizers and water treatment chemicals and robust demand for high-purity tantalum oxide, yet its price-to-book ratio has remained below 1.0 since September 2024. The company attributes this valuation gap to insufficiently articulated growth strategies and is responding by raising its 2028 medium-term targets for sales and operating profit, committing to aggressive investment in growth businesses, sustainability transformation, stronger governance and risk management, and enhanced communication with investors and shareholder returns.
To support its Long-Term Vision 2050, Taki Chemical is reinforcing its three business pillars of agriculture, chemicals, and real estate, while seeking synergies from its newly consolidated subsidiary Rakuto Chemical Industry in biostimulants and eco-friendly water treatment products. Management plans include bolstering disclosure through enriched sustainability reporting, more frequent investor briefings, and systematic feedback of investor views into corporate decision-making, with the aim of improving market recognition, lifting ROE, and closing the discount between its share price and underlying net asset value.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen4266.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.
Taki Chemical Co., Ltd. released supplementary materials on its consolidated financial results for the fiscal year ended December 31, 2025, detailing earnings performance, segment results, balance sheet data and cash flow trends. The disclosure also covers dividend information, progress under the company’s “Medium-term Management Plan 2028,” and a consolidated earnings forecast for the fiscal year ending December 31, 2026, signaling how management intends to drive growth and allocate capital across its multi-segment operations.
The materials break down performance across key business units, including agriculture, chemicals, real estate, construction materials, petroleum and transportation, highlighting how each segment contributed to overall results and key performance indicators. By tying current-year results to the milestones and basic policies of the Medium-term Management Plan 2028, the company provides stakeholders with a view of its strategic trajectory and expectations for future operating and financial performance, including projected earnings for 2026.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen4266.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.
Taki Chemical reported solid results for the fiscal year ended December 31, 2025, with revenue rising 7.9% year on year to ¥41.98 billion and operating profit up 18.6% to ¥3.16 billion. Profit attributable to owners of the parent jumped 42.5% to ¥3.28 billion, lifting basic earnings per share to ¥389.05 and pushing the equity ratio to 65.3% as total assets expanded to ¥65.65 billion.
Operating cash flow declined but remained positive at ¥2.31 billion, while the company continued to invest and returned more cash to shareholders, raising its year-end dividend to ¥75 per share from ¥55 a year earlier and planning a further increase to ¥80 for 2026. Management forecasts modest top-line growth to ¥43.0 billion in 2026 but expects a double-digit decline in profits as operating income is projected to fall 22.6% and net profit 19.1%, indicating a more challenging earnings environment despite ongoing commitment to dividend growth.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen4266.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.
Taki Chemical Co., Ltd. has completed the payment procedures for the disposal of treasury shares as restricted stock to its Employees’ Stockholding Association, under a previously approved plan to grant company stock to employees via the association. Due to partial forfeiture of rights by some association members, the number of shares disposed was reduced from the initial maximum plan to 40,964 shares, lowering the total disposal amount to ¥161.2 million, and the company stated that this adjustment will not affect its earnings forecast for the current fiscal year.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen3915.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.
Taki Chemical Co., Ltd. has announced an extraordinary income gain from the sale of certain investment securities, totaling ¥584 million, as part of a strategic move to enhance capital efficiency and governance by reducing cross-shareholdings. This financial maneuver is expected to positively impact the company’s financial results for the fiscal year ending December 2025, with a total of ¥690 million recorded as extraordinary income in consolidated financial statements, aligning with previously revised earnings forecasts.
The most recent analyst rating on (JP:4025) stock is a Hold with a Yen3915.00 price target. To see the full list of analyst forecasts on Taki Chemical Co., Ltd. stock, see the JP:4025 Stock Forecast page.